STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
Ontology highlight
ABSTRACT: Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with hitherto unseen responses at advanced and metastatic stages of the disease. However, the aggressive brain tumor glioblastoma (GBM) is highly immunosuppressive and remains largely refractory to current immunotherapeutic approaches. The stimulator of interferon genes (STING) DNA sensing pathway has emerged as a next-generation immunotherapy target with potent local immune stimulatory properties. Here, we investigated the status of the STING pathway in GBM and the modulation of the brain tumor microenvironment (TME) with the STING agonist ADU-S100. Our data reveal the presence of STING in human GBM specimens, where it stains strongly in the tumor vasculature. We show that human GBM explants can respond to S
SUBMITTER: Berger G
PROVIDER: S-EPMC9282249 | biostudies-literature | 2022 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA